REFERENCES
- Adam H. K., Douglas E. J., Kemp J. V. The metabolism of tamoxifen in humans. Biochem. Pharmacol 1979; 27: 145–147, [CSA]
- Allen K. E., Clark E. R., Jordan V. C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 1980; 71: 83–91, [INFOTRIEVE], [CSA]
- Bentrem D., Fox J. E., Pearce S. T., Liu H., Pappas S., Kupfer D., Zapf J. W., Jordan V. C. Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res 2003; 63: 7490–7496, [INFOTRIEVE], [CSA]
- Brzozowski A. M., Pike A. C., Dauter Z., Hubbard R. E., Bonn T., Engstrom O., Ohman L., Greene G. L., Gustaffson J. A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753–758, [INFOTRIEVE], [CROSSREF], [CSA]
- Bulger W. H., Feil V. J., Kupfer D. Role of hepatic monooxygenases in generating estrogenic metabolites from methoxychlor and from its identified contaminants. Mol. Pharmacol 1985; 27: 115–124, [INFOTRIEVE], [CSA]
- Bulger W. H., Kupfer D. Studies on the induction of rat uterine ornithine decarboxylase by DDT analogs. I. Comparison with estradiol-17 beta activity. Pest. Biochem. Physiol 1978; 8: 253–262, [CROSSREF], [CSA]
- Bulger W. H., Kupfer D. Estrogenic action of DDT analogs. Am. J. Ind. Med 1983; 4: 163–173, [INFOTRIEVE], [CSA]
- Bulger W. H., Muccitelli R. M., Kupfer D. Interactions of chlorinated hydrocarbon pesticides with the 8S estrogen-binding protein in rat testes. Steroids 1978a; 32, [CROSSREF], [CSA]
- Bulger W. H., Muccitelli R. M., Kupfer D. Interactions of methoxychlor, methoxychlor base-soluble contaminant, and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane with rat uterine estrogen receptor. J. Toxicol. Environ. Health 1978b; 4: 881–893, [INFOTRIEVE], [CSA]
- Bulger W. H., Muccitelli R. M., Kupfer D. Studies on the in vivo and in vitro estrogenic activities of methoxychlor and its metabolites: role of hepatic mono-oxygenase in methoxychlor activation. Biochem. Pharmacol 1978c; 27: 2417–2423, [INFOTRIEVE], [CROSSREF], [CSA]
- Bulger W. H., Muccitelli R. M., Kupfer D. Studies on the induction of rat uterine ornithine decarboxylase by DDT analogs. II. Kinetic characteristics of ornithine decarboxylase induced by DDT analogs and estradiol. Pest. Biochem. Physiol 1978d; 27: 263–270, [CROSSREF], [CSA]
- Bulger W. H., Temple J. E., Kupfer D. Covalent binding of [14C]methoxychlor metabolite(s) to rat liver microsomal components. Toxicol. Appl. Pharmacol 1983; 68: 367–374, [INFOTRIEVE], [CROSSREF], [CSA]
- Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br. J. Cancer 1971; 25: 270–275, [INFOTRIEVE], [CSA]
- Dodds E. C., Lawson W. Synthetic oestrogenic agents without the phenanthrene nucleus. Nature 1936; 137: 996, [CSA]
- EBCTCG. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N. Engl. J. Med 1988; 319: 1681–1692, [CSA]
- Fromson J. M., Pearson S., Bramah S. The metabolism of tamoxifen (ICI 46,474) Part II in femal patients. Xenobiotica 1973; 3: 711–713, [INFOTRIEVE], [CSA]
- Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993; 53: 3919–3924, [INFOTRIEVE], [CSA]
- Han X. L., Liehr J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 1992; 52: 1360–1363, [INFOTRIEVE], [CSA]
- Hard G. C., Iatropoulos M. J., Jordan K., Radi L., Kaltenberg O. P., Imondi A. R., Williams G. M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993; 53: 4534–4541, [INFOTRIEVE], [CSA]
- Harper M. J., Walpole A. L. Mode of action of I.C.I. 46,474 in preventing implantation in rats. J. Endocrinol 1967a; 37: 83–92, [INFOTRIEVE], [CSA]
- Harper M. J., Walpole A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil 1967b; 13: 101–119, [INFOTRIEVE], [CSA]
- Hoagland H. The Road to Yesterday. Worcester, MA 1974
- Hunter R. E., Jordan V. C. Detection of the 8 S oestrogen-binding component in human uterine endometrium during the menstrual cycle. J. Endocrinol 1975; 65: 457–458, [INFOTRIEVE], [CSA]
- Ireland J. S., Mukku V. R., Robison A. K., Stancel G. M. Stimulaation of uterine deoxyribonucleic acid synthesis by 1,1,1-trichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane (o, p'DDT). Biochem. Pharmacol 1980; 29: 1469–1474, [INFOTRIEVE], [CROSSREF], [CSA]
- Jensen E. V., Block G. E., Smith K., DeSombre E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr 1971; 34: 55–70, [INFOTRIEVE], [CSA]
- Jensen E. V., Jacobson H. I. Basic guides to the mechanism of estrogen action. Recent Progr. Hormone Res 1962; 18: 387–414, [CSA]
- Jiang S. Y., Jordan V. C. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst 1992; 84: 580–591, [PUBMED], [INFOTRIEVE], [CSA]
- Jordan V. C. Prolonged antioestrogenic activity of ICI 46, 474 in the ovariectomized mouse. J. Reprod. Fertil 1975; 42: 251–258, [INFOTRIEVE], [CSA]
- Jordan V. C. Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery 2003a; 2: 205–213, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jordan V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines Part II: Clinical Considerations and New Agents. J. Med. Chem 2003b; 46: 1082–1111, [CSA]
- Jordan V. C., Collins M. M., Rowsby L., Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol 1977; 75: 305–316, [INFOTRIEVE], [CSA]
- Jordan V. C., Koerner S. Inhibition of oestradiol binding to mouse uterine and vaginal oestrogen receptors by triphenylethylenes. J. Endocrinol 1975a; 64: 193–194, [INFOTRIEVE], [CSA]
- Jordan V. C., Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur. J. Cancer 1975b; 11: 205–206, [INFOTRIEVE], [CSA]
- Jordan V. C., Schafer J. M., Levenson A. S., Liu H., Pease K. M., Simons L. A., Zapf J. W. Molecular classification of estrogens. Cancer Res 2001; 61: 6619–6623, [INFOTRIEVE], [CSA]
- Juedes M. J., Kupfer D. Role of P-450c in the formation of a reactive intermediate of chlorotrianisene (TACE) by hepatic microsomes from methylcholanthrane treated rats. Drug Metab. Dispos 1990; 18: 131–137, [INFOTRIEVE], [CSA]
- Kennedy B. J. Hormone therapy for advanced breast cancer. Cancer 1965; 18: 1551–1557, [INFOTRIEVE], [CSA]
- Kupfer D. Effects of pesticides and related compounds on steroid metabolism and function. CRC Crit. Rev. Toxicol 1975; 4: 83–124, [INFOTRIEVE], [CSA]
- Kupfer D. Interactions of chlorinated hydrocarbons with steroid hormones. Fed. Proc 1976; 35: 2603–2608, [INFOTRIEVE], [CSA]
- Kupfer D., Bulger W. H. Studies on the mechanism of estrogenic actions of o, p'DDT: interactions with the estrogen receptor. Pest. Biochem. Physiol 1976; 6: 567–570, [CROSSREF], [CSA]
- Kupfer D., Bulger W. H. Interactions of o, p'DDT with the estrogen-binding protein (EBP) in human mammary and uterine tumors. Res. Commun. Chem. Pathol. Pharmacol 1977; 16: 451–462, [INFOTRIEVE], [CSA]
- Kupfer D., Bulger W. H. A novel in vitro method for demonstrating proestrogens: metabolism of methoxychlor and o, p'DDT by liver microsomes in the presence of uteri and effects of intracellular distribution of estrogen receptors. Life Sci 1979; 25: 975–984, [INFOTRIEVE], [CROSSREF], [CSA]
- Kupfer D., Bulger W. H. Inactivation of the uterine estrogen receptor binding of estradiol during P-450 catalyzed metabolism of chlorotrianisene (TACE). FEBS Lett 1990; 261: 59–62, [INFOTRIEVE], [CROSSREF], [CSA]
- Levenson A. S., Catherino W. M., Jordan V. C. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol 1997; 60: 261–268, [INFOTRIEVE], [CROSSREF], [CSA]
- Levenson A. S., Jordan V. C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 1998; 58: 1872–1875, [INFOTRIEVE], [CSA]
- Li H. C., Mani C., Kupfer D. Reversible and time-dependent inhibition of the hepatic cytochrome P450 steroidal hydroxylases by the proestrogenic pesticide methoxychlor in rat and human. J. Biol. Chem 1993; 8: 195–206, [CSA]
- Lieberman M. E., Gorski J., Jordan V. C. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J. Biol. Chem 1983a; 258: 4741–4745, [INFOTRIEVE], [CSA]
- Lieberman M. E., Jordan V. C., Fritsch M., Santos M. A., Gorski J. Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J. Biol. Chem 1983b; 258: 4734–4740, [INFOTRIEVE], [CSA]
- Lippman M. E., Chabner B. A. National Institutes of Health Consensus Development Conference: Adjuvant chemotherapy and endocrine therapy for breast cancer. Editorial Overview. NCI Monograph 1986; 1: 5–10, [CSA]
- Liu H., Lee E.-S., Reyes A. D. L., Zapf J. W., Jordan V. C. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor {{alpha}} complex. Cancer Res 2001; 61: 3632–3639, [INFOTRIEVE], [CSA]
- MacGregor Schafer J., Liu H., Bentrem D. J., Zapf J. W., Jordan V. C. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000; 60: 5097–5105, [INFOTRIEVE], [CSA]
- Mani C., Gelboin H. V., Park S. S., Pearce R., Parkinson A., Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-Demethylation and 4-Hydroxylation. Drug Metab. Dispos 1993a; 21: 645–656, [INFOTRIEVE], [CSA]
- Mani C., Hodgson E., Kupfer D. Metabolism of the antimammaary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-Oxidation. Drug Metab. Dispos 1993b; 21: 657–661, [INFOTRIEVE], [CSA]
- Mani C., Kupfer D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res 1991; 51: 6052–6058, [INFOTRIEVE], [CSA]
- Mani C., Pearce R., Parkinson A., Kupfer D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 1994; 15: 2715–2720, [INFOTRIEVE], [CSA]
- Murphy C. S., Parker C. J., McCague R., Jordan V. C. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Mol. Pharmacol 1991; 39: 421–428, [INFOTRIEVE], [CSA]
- Nelson J. A. Effects of dichlorodiphenyltrichloroethane (DDT) analogs and polychlorinated biphenyl (PCB) mixtures on 17beta-(3H) estradiol binding to rat uterine receptor. Biochem. Pharmacol 1974; 23: 447–451, [INFOTRIEVE], [CROSSREF], [CSA]
- Ousterhout J. M., Struck R. F., Nelson J. A. Estrogenic activities of methoxychlor metabolites. Biochem. Pharmacol 1981; 30: 2869–2871, [INFOTRIEVE], [CROSSREF], [CSA]
- Phillips D. H. Understanding the genotoxicity of tamoxifen?. Carcinogenesis 2001; 22: 839–849, [INFOTRIEVE], [CROSSREF], [CSA]
- Phillips D. H., Carmichael P. L., Hewer A., Cole K. J., Hardcastle I. R., Poon G. K., Keogh A., Strain A. J. Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 1996; 17: 89–94, [INFOTRIEVE], [CSA]
- Powles T. J., Hardy J. R., Ashley S. E., Farrington G. M., Cosgrove D., Davey J. B., Dowsett M., McKinna J. A., Nash A. G., Sinnett H. D. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer 1989; 60: 126–131, [INFOTRIEVE], [CSA]
- Rouanet P., Linares-Cruz G., Dravet F., Poujol S., Gourgou S., Simony-Lafontaine J., Grenier J., Kramar A., Girault J., Le Nestour E., Maudelonde T. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J. Clin. Oncol 2005; 23: 2980–2984, [INFOTRIEVE], [CROSSREF], [CSA]
- Shiau A. K., Barstad D., Loria P. M., Cheng L., Kushner P. J., Agard D. A., Greene G. L. The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927–937, [INFOTRIEVE], [CROSSREF], [CSA]
- Williams G. M., Iatropoulos M. J., Djordjevic M. V., Kaltenberg O. P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14: 315–317, [INFOTRIEVE], [CSA]
- Wolf D. M., Jordan V. C. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Br. Cancer Res. Treat 1994; 31: 129–138, [CROSSREF], [CSA]